# OnCo record nct06591520 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06591520/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06591520", "NCT06591520" ;
  schema:name "AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer"@en ;
  schema:description "A phase 3 trial of Cisplatin, Gemcitabine, Gemcitabine + cisplatin and Durvalumab in biliary tract cancer, run by Akeso, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06591520/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06591520> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-10-20" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/akeso/> .